ACM
ALGS icon

Altium Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Altium Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,340
Closed -$519K – 136
2021
Q3 		$519K Buy
+1,340
New +$530K 0.14% 104

Other funds holding ALGS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Altium Capital Management's ALGS Position: Q4 2021 in Review

Altium Capital Management sold out of Aligos Therapeutics (ALGS) in Q4 2021, closing a stake of 1,340 shares — an estimated $519K sold.

Altium Capital Management first reported a position in ALGS in Q3 2021 and held it in 1 quarter. The position peaked at $519K in Q3 2021. 71 funds tracked by Wall St. Rank hold ALGS as of Q4 2021.

  • Altium Capital Management reported no remaining Aligos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 1,340 Aligos Therapeutics shares in Q4 2021, an estimated $519K.
  • Altium Capital Management first reported a position in Aligos Therapeutics in Q3 2021 and held it in 1 quarter.
  • Altium Capital Management's Aligos Therapeutics position peaked at $519K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.